MONISSA SOLBERG: Open Payments
NPI 1164658027 · RIVERSIDE, RI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,455 in 127 payments from 15 companies in 2025. Trend: 2023 $3,131 · 2024 $2,981 · 2025 $2,455
Food & beverage: $2,336Education: $119
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 9 | $286 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $265 |
| Neurocrine BioSciences, Inc. | 16 | $261 |
| Axsome Therapeutics, Inc. | 12 | $247 |
| Vanda Pharmaceuticals Inc. | 8 | $220 |
| E.R. Squibb & Sons, L.L.C. | 12 | $210 |
| Alkermes, Inc. | 11 | $205 |
| Supernus Pharmaceuticals, Inc. | 12 | $172 |
| Collegium Pharmaceutical, Inc. | 9 | $156 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $123 |
Products named: TRINTELLIX, INGREZZA, Auvelity, FANAPT, COBENFY, AUSTEDO XR, REXULTI, Qelbree.
Industry payments across RI — which companies pay providers there.
